[Dapoxetine for premature ejaculation: Advances in clinical studies]

Area of Science:

• Pharmacology
• Urology
• Sexual Medicine

Background:

• Premature ejaculation (PE) is a prevalent sexual dysfunction affecting many men globally.
• Selective serotonin reuptuptake inhibitors (SSRIs) are commonly used, but specific treatments for PE are limited.
• Dapoxetine represents a novel SSRI developed for the on-demand treatment of PE.

Purpose of the Study:

• To evaluate the efficacy and safety of dapoxetine for treating premature ejaculation (PE).
• To assess dapoxetine's pharmacokinetic profile, including absorption, action speed, and half-life.
• To compare dapoxetine's safety and tolerability with traditional SSRIs.

Main Methods:

• Clinical trials were conducted across diverse populations and geographical areas.
• Data collection focused on intravaginal ejaculation latency time (IELT) and patient-reported outcomes.
• Adverse events associated with dapoxetine use were systematically recorded and analyzed.

Main Results:

• Dapoxetine demonstrated significant effectiveness in prolonging IELT in PE patients.
• The medication showed rapid absorption and action, suitable for on-demand use.
• Dapoxetine exhibited a favorable safety profile with generally mild adverse events like nausea and dizziness, and few severe cases.

Conclusions:

• Dapoxetine is an effective and well-tolerated oral treatment for premature ejaculation (PE).
• Its pharmacokinetic advantages make it a practical option for on-demand therapy.
• Dapoxetine offers a better safety and tolerability profile compared to traditional SSRIs for PE management.